Option chain shows key data for Molecular Partners's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Molecular Partners.

Molecular Partners (NASDAQ:MOLN) Stock, Option Chain

Molecular Partners

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Movers

News

Intraday Update

Markets

Trading Ideas

BBIO

COIN

CYRX

FUFU

INSP

MOLN

MSTR

NVDA

SIRI

SMCI

ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday

movers image

AAGR

ADTN

ALUR

APLD

AREB

ASAN

BNAI

CABA

CDMO

CIFR

CLOV

CRKN

DMTK

GOSS

IPDN

KAVL

KRKR

MBIO

MINM

ORGS

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RELI

SHCR

SMTK

SPEC

SRPT

SWBI

TPHS

TREX

WAVE

ZCAR

Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Pre-Market Outlook

BRNS

ENSC

LGHL

MGOL

ONDS

SLDB

TRVN

Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket

Molecular Partners AG - American Depositary Shares

Molecular Partners AG

Press Releases

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Health Care

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

General

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Alector

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

C4 Therapeutics

Cargo Therapeutics

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Genfit

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inhibrx Biosciences

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lyell Immunopharma

Monopar Therapeutics

Nanobiotix

Ocugen

Puma Biotechnology

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

JP Morgan

SVB Leerink

Comments

Molecular Partners

Molecular Partners (MOLN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga